创新药ETF建信(159835)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-11,679,349.49 |
4,955,750.59 |
16,518,674.09 |
-15,984,914.29 |
| 利息合计 |
20,815.62 |
36,173.39 |
15,989.64 |
42,345.87 |
| 其中:存款利息收入 |
20,815.62 |
36,173.39 |
15,989.64 |
42,345.87 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-5,647,963.25 |
693,943.05 |
-2,419,522.62 |
-15,128,766.93 |
| 其中:股票投资收益 |
-8,515,823.80 |
-951,000.82 |
-3,397,386.53 |
-16,416,668.20 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
2,867,860.55 |
1,644,943.87 |
977,863.91 |
1,287,901.27 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-6,348,075.50 |
4,314,570.81 |
18,989,945.03 |
-1,142,980.67 |
| 其他收入 |
295,873.64 |
-88,936.66 |
-67,737.96 |
244,487.44 |
| 费用 |
1,041,612.95 |
1,276,967.40 |
510,546.28 |
818,733.51 |
| 管理人报酬 |
751,476.94 |
807,472.85 |
298,176.01 |
458,944.57 |
| 基金托管费 |
150,295.41 |
161,494.55 |
59,635.23 |
91,788.94 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
139,840.60 |
308,000.00 |
152,735.04 |
268,000.00 |
| 利润总额 |
-12,720,962.44 |
3,678,783.19 |
16,008,127.81 |
-16,803,647.80 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年